MarketCap
Amphastar Pharmaceuticals AMPH
$ 24.06
1.16%
Facebook
X
Telegram
Amphastar Pharmaceuticals Accounts Receivables | AMPH
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 M | 136 M | 115 M | 88.8 M | 78.8 M | 66 M | 45.4 M | 52.2 M | 36 M | 26.8 M | 33.2 M | 22.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 144 M | 22.9 M | 70.4 M |
Quarterly Accounts Receivables Amphastar Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 145 M | 148 M | 147 M | 133 M | 145 M | 136 M | 140 M | 131 M | - | 115 M | 119 M | - | 101 M | 88.8 M | - | 80.8 M | 73.2 M | 78.8 M | 78.1 M | 67.9 M | 77.9 M | 66 M | 66 M | 66 M | 66 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 36 M | 36 M | 36 M | 36 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 24.6 M | 24.6 M | 24.6 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 148 M | 22.9 M | 65.5 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 5.71 | 7.24 % | $ 700 M |  USA |
 |
AbbVie
ABBV
|
12.6 B | $ 261.51 | 1.66 % | $ 463 B | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 11.09 | 1.84 % | $ 3.31 B |  Canada |
 |
Agenus
AGEN
|
1.83 M | $ 7.16 | 3.17 % | $ 213 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.45 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
3 | $ 5.39 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
3.43 M | $ 33.38 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
3 M | $ 3.29 | 2.94 % | $ 194 M |  China |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
672 K | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
50.4 M | $ 24.82 | 2.56 % | $ 3.77 B | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
233 K | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Cyclerion Therapeutics
CYCN
|
1 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
167 K | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.45 M | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
29.1 M | $ 1.11 | 3.76 % | $ 141 M |  Schweiz |
 |
Aridis Pharmaceuticals
ARDS
|
1 M | - | 17.91 % | $ 11.1 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
121 M | $ 27.48 | 0.04 % | $ 4.63 B | USA |
 |
AIM ImmunoTech
AIM
|
7 K | $ 0.22 | 0.05 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
158 M | $ 9.15 | 0.16 % | $ 2.18 B | USA |
 |
SQZ Biotechnologies Company
SQZ
|
3 M | - | 57.95 % | $ 12.8 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
Achieve Life Sciences
ACHV
|
8 K | $ 7.28 | 3.12 % | $ 317 M | USA |
 |
Baudax Bio
BXRX
|
335 K | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
1.54 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
277 K | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
411 K | - | - | $ 3.74 B | USA |
 |
Akebia Therapeutics
AKBA
|
47 M | $ 0.98 | 3.01 % | $ 252 M | USA |
 |
Avid Bioservices
CDMO
|
16.6 M | - | - | $ 789 M | USA |